Overview
Switzerland CDMO's 2025 revenue rose 15.6% but missed analyst expectations
EBITDA jumped 84% with margin up to 12%, driven by higher production and improved operations
Company expects 2026 revenue growth of 20-25% and further margin improvement
Outlook
PolyPeptide expects 2026 revenue to grow 20-25% versus 2025 at constant currency rates
Company sees 2026 EBITDA margin rising to mid- to high-teens
Capital expenditures in 2026 expected at 15-20% of revenue
Result Drivers
METABOLICS DEMAND - Co said strong demand for peptide-based therapeutics, especially in metabolics, drove revenue growth
CAPACITY EXPANSION - Successful ramp-up and utilization of new large-scale SPPS facility in Belgium contributed to higher production volumes
OPERATIONAL IMPROVEMENTS - Improved operational performance and product mix supported higher EBITDA margin
Company press release: ID:nEQ9DN61Qa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
EUR 389.33 mln
EUR 399.44 mln (6 Analysts)
FY Capex
EUR 109.98 mln
FY Cash Flow from Operating Activities
EUR 77.51 mln
FY EBIT
EUR 8.69 mln
FY EBITDA
EUR 46.76 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for PolyPeptide Group AG is CHF38.00, about 55.1% above its March 11 closing price of CHF24.50
The stock recently traded at 63 times the next 12-month earnings vs. a P/E of 149 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)